Boardroom Alpha
8-K primary document
PHGE · Current Report (Form 8-K) · Filed March 19, 2026

Biomx Inc8-K exhibit

ea028258201ex4-1.htm

Exhibit 4.1

 

Amendment to Warrant

 

Reference is made to the form of warrants issued in connection with the Securities Purchase Agreement between BiomX Inc. (the “Company” and Pyu Pyu Capital LLC (the “Investor”) dated as of December 26, 2025 for a private placement transaction of an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par value $0.0001 per share, wherein the Company issued warrant (the “Warrants”) to purchase shares of the Company’s common stock with an exercise period of five (5) years and at an initial exercise price of $2.00. The Form of Warrant is attached as as Exhibit 4.2 to the Company current report on Form 8-K filed on December 28, 2025.

 

Effective March 13, 2026, the Warrant is amended as follows (all capitalized terms not otherwise defined shall have the meanings attached to such terms in the Warrant).

 

1.The Termination Date is hereby amended to December 26, 2026.

 

2.The Exercise Price specified inn Section 2(b) shall be reduced to $1.00

 

3.The determination of A in Section 2 ( c) shall be rewritten in its entirety to read as follows

 

“(A) = as applicable: (i) the lowest VWAP on the five (5) Trading Days immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the lowest VWAP on the five (5) Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the lowest VWAP on the the five (5) Trading Days preceding the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;”

 

4.All references to the Warrants shall include and refer to this amendment to Warrants (the “Amendment to Warrant”)

 

5.Except as herein amended, all other terms and conditions in the Warrant shall continue in full force and effect.

 

 

 

 

IN WITNESS WHEREOF, the Company has caused this Amendment to Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

  BiomX Inc.
     
  By: /s/ Michael Oster
    Name: Michael Oster
    Title: CEO

 

Agreed to as of March 13, 2026

 

PYU PYU CAPITAL, LLC

 

By: /s/ Rueven Yeganeh  
Name: Rueven Yeganeh  
Title: Manager  

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer